TY - JOUR T1 - Business Shutdowns and COVID-19 Mortality JF - medRxiv DO - 10.1101/2020.10.06.20207910 SP - 2020.10.06.20207910 AU - Gabriele Ciminelli AU - Sílvia Garcia-Mandicó Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/07/2020.10.06.20207910.abstract N2 - Governments around the world have adopted unprecedented policies to deal with COVID-19. This paper zooms in on business shutdowns and investigates their effectiveness in reducing mortality. We leverage upon highly granular death registry data for over 4,000 Italian municipalities in a diff-in-diff approach that allows us to credibly mitigate endogeneity concerns. Our results, which are robust to controlling for a host of co-factors, offer strong evidence that business shutdowns are very effective in reducing mortality. We calculate that the death toll from the first wave of COVID-19 in Italy would have been twice as high in their absence. Our findings also highlight that timeliness is key – by acting one week earlier, the government could have reduced the death toll by an additional 25%. Finally, our estimates suggest that shutdowns should be targeted: closing shops, bars and restaurants saves the most lives, while shutting down manufacturing and construction activities has only mild effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No clinical trials/patients involvedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request ER -